Advanced Search
Current and Breaking News for Professionals, Consumers and Media

Click here to learn how to advertise on this site and for ad rates.

FDA Approval Author: Staff Editor Last Updated: Sep 7, 2017 - 10:06:33 PM

Trimel Receives FDA Approval for Natesto™ Nasal Gel to Treat Men with Low Testosterone

By Staff Editor
May 28, 2014 - 9:13:16 PM

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon Sign up for our Ezine
For Email Marketing you can trust

Email this article
 Printer friendly page

NatestoTM is the first nasal testosterone replacement therapy approved by FDA

( - TORONTO, May 28, 2014 /CNW/ - Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that the United States Food and Drug Administration (FDA) has approved NatestoTM (testosterone), formerly CompleoTRTTM, the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. NatestoTM is self-administered via a nasal applicator thereby minimizing the risk of secondary exposure to testosterone of women or children.

"In my practice I regularly encounter men demonstrating symptoms of hypogonadism and physicians will increasingly see this as the North American population ages," said Dr. Jeffrey Rosen, the medical director and founder of Clinical Research of South Florida (CRSA). "For these patients seeking to restore their testosterone levels, NatestoTM will offer an alternative delivery system that is safer and more convenient than the other options currently available on the market."

It is conservatively estimated that nearly 13 million American men may have low testosterone levels.  Current treatment guidelines focus on the restoration of the physiological testosterone level through the use of exogenous testosterone preparations, which include topical gels applied by the hands, subcutaneous pellets, transdermal patches, intramuscular injections, oral tablets, as well as a buccal patch.

"The FDA approval for NatestoTM is a major achievement for our company, as it validates our clinical research and development efforts, as well as reinforces our commitment to provide innovative treatment options for patients," said Tom Rossi, Trimel Pharmaceuticals CorporationPresident and CEO. "Men suffering from "Low T" will now have a different option to raise their testosterone levels.  This novel route of administration will enable men to take this therapy in mere seconds, without worrying about the risk associated with transferring the product to women or children.  We are now focused on getting NatestoTM to market as expeditiously as possible so that appropriate patients can have access to it."

About Male Hypogonadism

Male hypogonadism, or low testosterone, is a condition in which the testicles, hypothalamus or pituitary gland is affected by disease or damage that results in inhibiting hormone and testosterone secretion. Signs and symptoms associated with male hypogonadism include erectile dysfunction and decreased sexual desire, fatigue and loss of energy, depressed mood, osteoporosis and regression of secondary sexual characteristics.

About NatestoTM (testosterone) Nasal Gel

Indications and Usage

NatestoTM is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone including:

  • Primary hypogonadism (congenital or acquired)
  • Hypogonadotropic hypogonadism (congenital or acquired)

Limitations of Use

  • Safety and efficacy of NatestoTM in males less than 18 years old have not been established


NatestoTM for intranasal use is available as a metered-dose pump.  One pump actuation delivers 5.5 mg of testosterone. The recommended dose of NatestoTM is 11 mg of testosterone (two pump actuations, one per nostril), applied intranasally three times daily for a total daily dose of 33 mg.


  • Men with carcinoma of the breast or known or suspected prostate cancer
  • Pregnant or breast-feeding women. Testosterone may cause fetal harm

Warnings and Precautions

  • Nasal adverse reactions:  nasal signs and symptoms should be monitored.  NatestoTM is not recommended for use in patients with chronic nasal conditions or alterations in nasal anatomy
  • Monitor patients with benign prostatic hyperplasia (BPH) for worsening of signs and symptoms of BPH
  • Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients using testosterone products.  Evaluate patients with signs or symptoms consistent with DVT or PE
  • Women and children should not use NatestoTM
  • Edema with or without congestive heart failure (CHF) may be a complication in patients with preexisting cardiac, renal, or hepatic disease
  • Exogenous administration of androgens may lead to azoospermia
  • Sleep apnea may occur in those with risk factors
  • Monitor serum testosterone, prostate-specific antigen (PSA), hemoglobin, hematocrit, liver function tests, and lipid concentrations periodically

Adverse Reactions

The most common adverse reactions (incidence ≥3%) to NatestoTM observed in clinical trials were an increase in prostate specific antigen (PSA), headache, rhinorrhea, epistaxis, nasal discomfort, nasopharyngitis, bronchitis, upper respiratory tract infection, sinusitis and nasal scab.

About the NatestoTM Phase III Study

NatestoTM was evaluated in a multicenter, open-label, 90-day Phase III trial that enrolled 306 hypogonadal men at 39 clinical research centers in the United States. The mean age of patients was 54 years with a range of 28 to 80 years. Of the 306 patients, 271 (89%) were Caucasian, 18 (6%) were African-American, 16 (5%) were Asian, and 1 (less than 1%) had race recorded as "Other." Patients were instructed to administer NatestoTM intranasally. During the NatestoTM treatment period (Days 1 to 90), 78 patients were treated with 33 mg of testosterone daily.  Of these, a total of 73 men were included in the statistical evaluation of efficacy on Day 90 based on the intent-to-treat (ITT) population with last observation carried forward (LOCF).  Ninety percent (90%) of these patients had Cavg within the normal range (300 to 1050 ng/dL) on Day 90.  The percentage of patients with Cavg below the normal range (less than 300 ng/dL) on Day 90 was 10% and no subject had a Cavg value exceeding 1050 ng/dL.

About Trimel

Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. For more information, please visit


For advertising/ promotion on, call Mike McCurdy at: 877-634-9180, or email at: [email protected] We have over 7,000 journalists as subscribers who can use our content.


Top of Page

FDA Approval
Latest Headlines

+ FDA Warns About Illegal Use of Injectable Silicone for Body Contouring and Associated Health Risks
+ FDA Warns of Potential Contamination in Multiple Brands of Drugs, Dietary Supplements
+ FDA Approves New Treatment to Reduce the Risk of Breast Cancer Returning
+ FDA Unveils Plan to Eliminate Orphan Designation Backlog
+ FDA Investigates Findings of Hepatitis A Linked to Frozen Tuna
+ FDA Approves New Novo Nordisk Treatment for Patients with Hemophilia
+ FDA Approves First Cancer Treatment for Any Solid Tumor With a Specific Genetic Feature
+ FDA Approves Drug to Treat ALS
+ FDA Approves Urea Cycle Disorder Treatment for Use in Children as Young as Two Months
+ Novartis Receives FDA Approval for Rydapt® in Newly Diagnosed FLT3-mutated Acute Yeloid Leukemia (AML)

Contact Us | Job Listings | Help | Site Map | About Us
Advertising Information | HND Press Release | Submit Information | Disclaimer

Site hosted by Sanchez Productions